airway, survival, and activation. 11 The development of agents that target IL-5 for treatment of asthma makes it imperative that clinicians have tools to identify patients with eosinophilic characteristics.
Eosinophilic asthma has been defined as airway eosinophilia using eosinophils in airway biopsies or bronchoalveolar lavage. However, bronchoscopy in asthmatics is impractical and not available for most clinicians. Induced sputum, used as a surrogate for airway biopsies, 8, [12] [13] [14] [15] [16] [17] [18] is cumbersome, may be risky in some patients, and sputum may not be produced by all patients. Sputum eosinophil levels may vary over time and can be influenced by the use of inhaled corticosteroids. 19 Blood eosinophils fit criteria as a clinically useful biomarker: measures are accessible at point of care and predict response to interventions. 10, 20, 21 Their ease of sampling makes them an appealing surrogate for airway samples. 22 Blood levels were used for the first large-scale study demonstrating efficacy of anti-IL-5 treatment 18 and have been used for subsequent studies. Despite the ease of measurement, unanswered questions about the use of blood eosinophils remain. Blood eosinophils do not consistently reflect airway eosinophil levels. [23] [24] [25] Moreover, the threshold blood eosinophil value used to predict a therapeutic response differs among studies and the baseline blood level has implications for the response to therapy. 18, [26] [27] [28] [29] If blood eosinophil levels are to be used for determining eligibility for new biologics, it would be important to understand whether these values are reproducible and stable. Few studies have examined the stability of blood eosinophil measures over time. Variability has been shown within 24 hours in a small population. 30, 31 A study of 82 individuals with and without mild asthma suggested a within-subject geometric coefficient of variation of 39.7%. 32 Post hoc analysis of clinical trials for mepolizumab suggests stability of blood eosinophil counts in patients enrolled based on their elevated baseline eosinophil count. 22, 33 The stability of blood eosinophil levels on repeated measurements in real-world populations remains poorly described.
The NYU/Bellevue Hospital Asthma Clinic (BHAC), located in the largest public hospital in New York City, is a longstanding program for referred, or self-referred patients with uncontrolled asthma. 34, 35 Upon evaluation in the program, most, although not all, of these patients fit criteria for severe or difficult-to-treat asthma. We examined the distribution of blood eosinophil levels in our clinical program since many might be candidates for biologic therapy. 
| Statistical analysis
To account for the skewness of blood eosinophil distribution, we applied logarithm transformation on blood eos measurements, and calculated individual mean and variance based on repeated measures of log eos for each subject. K-mean clustering algorithm with Euclidean distance metric was applied to cluster subjects into three groups based on their individual means and variances. Missing values were classified as unknown category. Continuous variables were compared across groups using Kruskal-Wallis test, and categorical variables were evaluated using chi-square test.
| RESULTS

| Patient characteristics
A total of 280 patients were evaluated at the adult BHAC during the 3-month ascertainment period. Among these patients, 61 were excluded: <2 blood eosinophil values (n = 28), no primary asthma diagnosis (n = 19), primary hypereosinophilic diagnosis or parasites (n = 7). The clinical characteristics of the remaining 219 patients are shown (Table 1 ). Patients were predominantly female (78%) with a mean age of 59 years. They had diverse race/ethnicity, with many classifying themselves as Hispanic. Many were overweight or obese, most were never smokers (65%) and few (5%) were current smokers.
The majority of patients (74%) were prescribed combination inhaled corticosteroids (ICS) and long-acting beta 2 agonist (LABA), with many (23%) also prescribed a long-acting muscarinic antagonist (LAMA) and leukotriene receptor antagonist (LTRA). Few, 6%, were receiving chronic oral prednisone. In the previous 12 months, 53% had received rescue prednisone and 14.6% had a hospitalization. A history of intubation for asthma was reported by 11%. The pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV 1 ) was reduced, but approached a normal value after bronchodilator. Most (59%) were atopic, with many having a sIgE to an indoor allergen.
The majority of patients received public insurance (Medicaid 56%, Medicare 14%) and 25% were uninsured.
| Distribution of individual blood eos levels
We first evaluated the distribution of blood eos levels over time (22) 22 (22) 26 (22) Race/Ethnicity, n (%)
White non-Hispanic 8 (4) 4 (4) 4 (3) 0.48
Black non-Hispanic 31 (14) 10 (10) 21 (18) Asian 10 (5) 6 (6) 4 (3) Hispanic 94 (43) 45 (44) 49 (42) Unknown/Other 76 (35) 37 (36) 39 (33) BMI, n (%)
37 (17) 19 (19) 18 (15) To understand whether our patients would fit criteria used for many of the anti-IL-5 trials, we determined how many of our patients had blood eos values that were consistently above or below a threshold of 300 cells/μL. As shown (red), only 6% (n = 13) of patients had levels that were repeatedly above 300. Nearly 50%
(n = 104) of our patients had levels that traversed the threshold of 300 cells/μL (blue). In contrast, 102 (46%) of our patients had levels that never reached a value of 300 cells/μL. Because of the possibility that some of these values were obtained during an asthma exacerbation, we performed a sensitivity analysis and reanalysed data after removing all samples obtained during an asthma HA. This resulted in the exclusion of 72 blood eos values; all individuals remained in the analysis. Despite this removal, only two subjects switched category as below or ever above 300 cells/μL. To assess for seasonal variation, we also used a mixed-effects model of repeated measures of blood eos (absolute or log values) and month. We did not observe any significant relationship between blood eos and time of year (data not shown). Because a cut-off value of 150 cells/μL has also been used as a threshold for therapeutic eligibility, 27, 37 we also used this value to evaluate our population. More patients fit this criterion: 24% of the patients had levels that were repeatedly above 150 cells/μL, 62% continued to have levels that crossed the threshold and 14% had levels repeatedly below the threshold value of 150 cells/μL (data not shown).
| Association of clinical characteristics with blood eos levels
To identify characteristics associated with higher or lower blood eosinophil counts, we examined characteristics of patients with eosinophil levels below or ever above 300 cells/μL (Table 1) . There were few differences in characteristics between these two groups. There was a suggestion of an association of higher total IgE with elevated eosinophils (P < 0.03).
| Variability patterns and level of blood eos
To further characterize variability of blood eos in our population, we used K-mean clustering algorithm and restricted our analysis to three clusters. Three clusters of patients were identified based on individual average blood eos value and variability within the repeated measures. The degree of variability was quantified using the SD of the log blood eos count (SD log eos). The analyses are shown in Table 2 and Figure 2 . As shown in Figure 2 , Cluster 1 (red circles, n = 62) had little variability in blood eos (SD log eos = 0.57) with a low geo- 
| Association of clinical characteristics with pattern of blood eos variability and level (clusters)
To identify characteristics associated with the pattern of blood eos variability and level, we examined characteristics of patients in each cluster (Table 3 ). There was a suggestion of more men in cluster 2.
Other demographic characteristics, including race/ethnicity, BMI and tobacco history did not differ between the clusters. Although not statistically significant for every parameter of control, there was a suggestion of less well-controlled asthma in cluster 2. Our data are consistent with the findings of Katz et al and Spector and Tan, 22, 31 as well as with sputum studies. 38 Mathur et al 32 report a large within-subject geometric coefficient of variation in 84 individuals; however, these patients had mild or no asthma, and the applicability to a more severe group remained in question.
In contrast to these studies, post hoc analyses of patients who were enriched for higher eosinophils at baseline and used a shorter observation time showed little variability. 22, 33 Our findings expand upon previous studies and reveal groups of patients who may or may not ever reach a defined blood eos threshold level.
Our data thus provide additional support to suggest that repeated Race/Ethnicity, n (%)
White non-Hispanic 1 (2) 3 (7) 4 (4) 0.27
Black non-Hispanic 6 (10) 9 (20) 16 (14) Asian 2 (3) 0 (0) 8
Hispanic 26 (42) 18 (41) 50 (44) Unknown/Not reported/Other 27 (43) 14 (32) 35 (31) BMI, n (%) Blood eos have been suggested to be associated with clinical characteristics in numerous studies. 10, 39, 40 However, these analyses were based on levels obtained at a single point in time and fail to take variability into account. Our scatter plot of the distribution of blood eos for each patient showed extensive variation within individuals. Using a defined threshold, we showed that there were three groups of patients: those that remained below and never crossed the threshold, those that remained above the threshold, and those that had levels that traversed the cut-off value. Our scatter plot
showed that nearly 50% of the patients failed to ever have a level ≤300 cells/μL, a finding consistent with studies of repeated sputum measures in which approximately 50% of patients had persistently low eosinophil levels. 41 Although there was a suggestion of an elevated total IgE with higher eosinophils, we could not identify clinical characteristics associated with being consistently above or below a threshold of ≤300 cells/μL, again providing support for the suggestion that repeated measures are needed for this determination.
Our analysis of patterns of variability and level, using a cluster analysis, revealed findings with potential important clinical implications. We identified three patterns: clusters 1 and 3, with little variability in their counts, but with differences in the eosinophil level.
Cluster 2, although small, had the greatest variability in blood counts.
This cluster was associated with more prescriptions for multiple controllers and greater hospitalization rates, suggesting an association of blood eos variability with underlying difficulty with control. These findings may be due to differences in intrinsic disease activity as manifest by fluctuating eosinophil levels, or may reflect a response to external stimuli, including that of allergens.
The variability of blood eosinophil counts raises the question of whether intrasubject variability affects response to agents that target IL-5. A higher baseline eosinophil count is associated with a clinical response to these agents 18, [26] [27] [28] 42 ; however, the importance of variability remains to be determined. Although patients in cluster 2, with more blood eosinophil variability, and cluster 3, with higher blood eosinophil levels but less variability could all be eligible for agents targeting IL-5, it is unclear whether the clinical response to agents that target IL-5 would be similar between patients in these clusters.
Blood eosinophils are derived from an eosinophil lineage-committed progenitor that requires the transcription factor GATA-1. 43, 44 Upon entry into circulation, eosinophils have a short half-life before distribution into diverse tissue sites, including the lung. Eosinophil survival transit time in the intravascular space and distribution into tissue sites is modified by numerous factors, 31, 43 and the multitude of steps that determine intravascular time make it likely that there would be variability in blood levels in an individual. Our data suggest heterogeneity in blood eosinophil variability and thus raise the question of whether variability is due to differences in underlying mechanisms particularly since cytokines in addition to IL-5 can stimulate eosinophil production and function. 11 Understanding whether variability patterns are due to different mechanisms would have important clinical implications.
There are limitations to our study. Variability of blood eos has been described in small samples over 24 hours 30, 31 ; we were not able to control time of samples. Although the possibility exists that seasonal exposures may regulate eosinophils, we did not observe a seasonal variation using a mixed-effects model. Some of the samples may have been obtained during a hospitalization; however, we did not observe an influence on subject status using a sensitivity analysis after removing values obtained at an asthma hospitalization. Our clusters were small, and we did not have an independent validation set. However, the cluster algorithm itself is an unsupervised learning algorithm, and thus, there is no real outcome variable against which to compare the clustered membership. Our population was derived from a program designed for patients with severe and difficult-totreat asthma with a high rate of hospitalization, intubations and prednisone use. These patients are not representative of a general population of patients with asthma; however, they are the group in which advanced therapeutics would most likely be considered. We used report of medications and we were unable to fully assess adherence. To obtain appropriate information on the role of medication use and blood eos, we would need a prospective study with reliable reporting of daily medication use. We reported variability of eosinophil blood levels obtained over a 5-year period. This long period of observation enhanced our ability to detect variations in eosinophil levels but may not be practical for clinical use. 
